Background: Chikungunya is a mosquito-borne disease caused by an arthritogenic alphavirus, with four genotypes: East Central South African (ECSA), West African, ECSA-diverged or Indian Ocean Lineage (IOL) and Asian lineage. Overall, the disease is self-limited; however, in some patients, joint pain and other non-specific symptoms can last for months or years. This systematic review and meta-analysis aims to estimate the proportion of people that self-report chikungunya-related chronic non-specific symptoms. Methods: Medline, EMBASE, Global Health Library and Scopus were searched for articles published before March 2017. Case-control, cohort, cross-sectional, clinical trials studies and outcome-independent case series were eligible. It was estimated that the proportion of patients who did not recover, by virus genotype, and by the time between disease onset and assessment of chronic symptoms. Results: A total of 38 studies were included in the review and 34 in the meta-analysis. Of 6532 chikungunya patients, 3157 did not recover fully after 3 months. The overall no recovery rate associated with chikungunya was 43% (95% CI, 35-52%); Inter-genotype group heterogeneity was observed, the highest prevalence in the ECSA-diverged genotype: 50% (95% CI; 40-60%), followed by the Asian lineage genotype: 36% (95% CI; 20-52%). After 12 months follow-up, the overall no-recovery rate was 21% (95% CI; 19-22%). Conclusion: The evidence suggests that the prevalence of chronic discomfort associated with chikungunya illness varies by virus lineage. The proportion of people that do not fully recovered after chikungunya was high and, therefore, health authorities must prepare to treat patients with symptoms of long-lasting chikungunya adequately addressing the physical, psychological and social needs.
Background: Chikungunya is a mosquito-borne disease caused by an arthritogenic alphavirus, with four genotypes: East Central South African (ECSA), West African, ECSA-diverged or Indian Ocean Lineage (IOL) and Asian lineage. Overall, the disease is self-limited; however, in some patients, joint pain and other non-specific symptoms can last for months or years. This systematic review and meta-analysis aims to estimate the proportion of people that self-report chikungunya-related chronic non-specific symptoms. Methods: Medline, EMBASE, Global Health Library and Scopus were searched for articles published before March 2017. Case-control, cohort, cross-sectional, clinical trials studies and outcome-independent case series were eligible. It was estimated that the proportion of patients who did not recover, by virus genotype, and by the time between disease onset and assessment of chronic symptoms. Results: A total of 38 studies were included in the review and 34 in the meta-analysis. Of 6532 chikungunya patients, 3157 did not recover fully after 3 months. The overall no recovery rate associated with chikungunya was 43% (95% CI, 35-52%); Inter-genotype group heterogeneity was observed, the highest prevalence in the ECSA-diverged genotype: 50% (95% CI; 40-60%), followed by the Asian lineage genotype: 36% (95% CI; 20-52%). After 12 months follow-up, the overall no-recovery rate was 21% (95% CI; 19-22%). Conclusion: The evidence suggests that the prevalence of chronic discomfort associated with chikungunya illness varies by virus lineage. The proportion of people that do not fully recovered after chikungunya was high and, therefore, health authorities must prepare to treat patients with symptoms of long-lasting chikungunya adequately addressing the physical, psychological and social needs.
Authors: Grace L Chen; Emily E Coates; Sarah H Plummer; Cristina A Carter; Nina Berkowitz; Michelle Conan-Cibotti; Josephine H Cox; Allison Beck; Mark O'Callahan; Charla Andrews; Ingelise J Gordon; Brenda Larkin; Rebecca Lampley; Florence Kaltovich; Jason Gall; Kevin Carlton; Jason Mendy; Doug Haney; Jeanine May; Amy Bray; Robert T Bailer; Kimberly A Dowd; Brittanie Brockett; David Gordon; Richard A Koup; Richard Schwartz; John R Mascola; Barney S Graham; Theodore C Pierson; Yeycy Donastorg; Nicolas Rosario; Jean William Pape; Bruno Hoen; André Cabié; Clemente Diaz; Julie E Ledgerwood Journal: JAMA Date: 2020-04-14 Impact factor: 56.272
Authors: Hilary Bower; Mubarak El Karsany; Abd Alhadi Adam Hussein Adam; Mubarak Ibrahim Idriss; Ma'aaza Abasher Alzain; Mohamed Elamin Ahmed Alfakiyousif; Rehab Mohamed; Iman Mahmoud; Omer Albadri; Suha Abdulaziz Alnour Mahmoud; Orwa Ibrahim Abdalla; Mawahib Eldigail; Nuha Elagib; Ulrike Arnold; Bernardo Gutierrez; Oliver G Pybus; Daniel P Carter; Steven T Pullan; Shevin T Jacob; Tajeldin Mohammedein Abdallah; Benedict Gannon; Tom E Fletcher Journal: PLoS Negl Trop Dis Date: 2021-04-30
Authors: M E Foeller; C Nosrat; A Krystosik; T Noel; P Gérardin; N Cudjoe; V Mapp-Alexander; G Mitchell; C Macpherson; R Waechter; A D LaBeaud Journal: BJOG Date: 2020-11-19 Impact factor: 6.531
Authors: Maira Sant Anna Genaro; Micheli Said de Marchi; Matheus Yung Perin; Isabelle Silva Cossô; Renata Dezengrini Slhessarenko Journal: Am J Trop Med Hyg Date: 2020-11 Impact factor: 2.345